BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

 
Alternative splicing variant of NRP/B promotes tumorigenesis of gastric cancer
Aram Kim 1,4,# (Research Professor), Bo Ram Mok 1,4,# (Postdoctoral Fellow), Soojung Hahn 2,3 (Research worker), Jongman Yoo2,3 (Professor), Dong Hyun Kim 4 (Professor), Tae-Aug Kim 1,4,* (Professor)
1Department of Biochemistry and 2Department of Microbiology, Institution of Basic Medical Science, School of Medicine, CHA University,
3Organoid research center, R&D Institute, Organoidsciences Ltd.,
4Department of Dermatology, Bundang CHA Medical Center, School of Medicine, CHA University
Abstract
Gastrointestinal cancer continues to be associated with a high mortality rate. Here, we report that the splice variant of NRP/B contributes to tumorigenic activity in highly malignant gastric cancer through dissociation from the tumor repressor, HDAC5. NRP/B mRNA expression is significantly higher in human gastric cancer tissues than in normal tissues. Further, high levels of both NRP/B splice variant and Lgr5, but not the full-length protein, are found in highly tumorigenic gastric tumor cells, but not in non-tumorigenic cells. The loss of NRP/B markedly inhibits cell migration and invasion, which reduces tumor formation in vivo. Importantly, the inhibition of alternative splicing increases the levels of NRP/B-1 mRNA and protein in AGS cells. The ectopic expression of full-length NRP/B exhibits tumor-suppressive activity, whereas NRP/B-2 induces the tumorigenesis of noninvasive human gastric cancer cells. The splice variant NRP/B-2 which loses the capacity to interact with tumor repressors promoted oncogenic activity, suggesting that the BTB/POZ domain in the N-terminus has a crucial role in the suppression of gastric cancer. Thus, the regulation of alternative splicing of the NRP/B gene can be a novel target for the treatment of gastrointestinal cancer.
Abstract, Accepted Manuscript(in press) [Submitted on February 23, 2022, Accepted on May 10, 2022]
  © KSBMB. All rights reserved. / Powered by INFOrang Co., Ltd